Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX® Intranasal Antiviral Protection Against SARS-CoV-2
July 07, 2020 07:00 ET
|
Nasus Pharma
TEL AVIV, Israel, July 07, 2020 (GLOBE NEWSWIRE) -- Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address...